Print

Proteostasis Therapeutics, Inc. Announces Expansion of Collaboration With The Scripps Research Institute to Broaden Cystic Fibrosis Program  
7/26/2012 10:10:35 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it has expanded its collaboration with The Scripps Research Institute (TSRI) to encompass an additional funded research project focused on biology and the testing of small molecule modulators of protein folding and trafficking for the treatment of cystic fibrosis (CF). This expansion follows the Company’s recently announced collaboration with the Cystic Fibrosis Foundation to research, develop, and commercialize therapies to treat patients with the most common mutation of the cystic fibrosis transmembrane conductance regulator (CFTR), Delta F508.
//-->